CCCC C4 Therapeutics

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY.

Fireside Chat Details:

Date: Wednesday, February 11, 2026

Time: 11:30 AM ET

A live webcast will be available on the Investors section of the company’s website at . An archived replay of the webcast will be available for approximately 90 days following the event.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit .

Contacts:

Investors:

Courtney Solberg

Associate Director, Investor Relations

Media:

Loraine Spreen

Senior Director, Corporate Communications & Patient Advocacy



EN
04/02/2026

Underlying

CCCCC4 Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Bio...

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY. Fireside Chat Details:Date: Wednesday, February 11, 2026 Time: 11:30 AM ET A live webcast will be available on the...

20h 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5...

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the gran...

January 26, 2026 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide a...

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways  Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 ...

January 14, 2026 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare C...

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida. Fireside Chat Details:Event: 8th Annual Evercore Healthcare ConferenceDate/Time: Wednesday, December 3rd, 2025 at 3:25 pm ET A ...

November 25, 2025 1 EN
 PRESS RELEASE
Free
CCCC C4 THERAPEUTICS

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recen...

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile  Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide ...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch